Can Tobramycin Be Given with Levofloxacin?
Yes, tobramycin can be safely co-administered with levofloxacin (Levaquin), and this combination is commonly used in clinical practice, particularly for treating serious Gram-negative infections including Pseudomonas aeruginosa.
No Pharmacokinetic Interactions
The FDA drug label for levofloxacin does not list tobramycin or any aminoglycosides as having clinically significant drug interactions 1. The documented drug interactions for levofloxacin are limited to:
- Chelating agents (antacids, iron, multivitamins with zinc)
- Warfarin
- Antidiabetic agents
- NSAIDs
- Theophylline
Tobramycin is notably absent from this list, indicating no known pharmacokinetic interference between these two antibiotics.
Clinical Evidence Supporting Combination Use
Synergistic Activity Against Gram-Negative Pathogens
Multiple studies demonstrate that levofloxacin and tobramycin can be used together effectively:
In bacterial keratouveitis: Topical tobramycin combined with topical and oral levofloxacin showed excellent efficacy, particularly against Pseudomonas aeruginosa (the most common pathogen in contact lens wearers), with significant visual improvement (p < 0.0001) 2.
Against ESBL-producing Klebsiella pneumoniae: Combination therapy with tobramycin and levofloxacin provided dramatic bacterial killing, though bactericidal activity was not always maintained over 24 hours 3.
Post-antibiotic effects: When combined with cefepime, both tobramycin and levofloxacin maintained their individual post-antibiotic effects, though cefepime slightly reduced the PAE of each drug 4.
Cystic Fibrosis Guidelines Support Concurrent Use
In CF patients with Pseudomonas aeruginosa infections, both drugs are recommended:
- Inhaled tobramycin is recommended for chronic use in CF patients ≥6 years with persistent P. aeruginosa to reduce exacerbations 5
- Levofloxacin is listed as an appropriate antimicrobial option in urologic prophylaxis guidelines alongside aminoglycosides including tobramycin 6
The European consensus on CF antibiotic therapy explicitly discusses using aminoglycosides (including tobramycin) in combination regimens, noting that combination therapy may slow drug resistance and result in synergy 7.
Practical Considerations
Monitoring Requirements
When using this combination, monitor for:
For tobramycin:
- Renal function (serum creatinine, CrCl)
- Ototoxicity (audiometry for prolonged use)
- Serum peak (Cmax 20-40 mg/L) and trough (Cmin <1 mg/L) levels
- Consider AUC24-guided dosing (target 80-120 mg/L·h) for optimal efficacy and safety 8
For levofloxacin:
- Renal function (both drugs are renally cleared)
- Blood glucose if patient is diabetic
- CNS effects (dizziness, seizures)
- Tendon pain (risk of tendinopathy/rupture)
Dosing Adjustments
Both drugs require renal dose adjustment:
- Levofloxacin: Adjust when CrCl <50 mL/min (750-1000 mg three times weekly) 9
- Tobramycin: Adjust dosing interval based on renal function; consider once-daily dosing (safer and equally efficacious as three-times-daily) 7
Common Pitfalls to Avoid
Additive nephrotoxicity: While no pharmacokinetic interaction exists, both drugs can cause nephrotoxicity. Monitor renal function closely, especially in patients with baseline renal impairment or receiving other nephrotoxic agents.
Ototoxicity from tobramycin: This is the primary toxicity concern with aminoglycosides. Baseline and periodic audiometry is warranted for prolonged therapy.
Levofloxacin absorption: Do not administer levofloxacin within 2 hours of antacids, iron, or multivitamins containing zinc, as these significantly reduce absorption 9.
Resistance considerations: While combination therapy may reduce resistance development, inappropriate use of fluoroquinolones can promote resistance. Reserve this combination for documented or highly suspected Gram-negative infections.
Clinical Bottom Line
Tobramycin and levofloxacin can be safely co-administered without dose adjustment for the drug interaction itself. This combination provides broad Gram-negative coverage with potential synergistic activity against Pseudomonas aeruginosa and other resistant organisms. The primary concerns are additive nephrotoxicity and individual drug-specific adverse effects (ototoxicity for tobramycin, tendinopathy for levofloxacin), which require appropriate monitoring but do not contraindicate concurrent use. Adjust doses based on renal function for each drug independently.